Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine

Dana Jones, Neil Parkin, Sarah E. Hudelson, Laura A. Guay, Philippa Musoke, Francis Mmiro, J. Brooks Jackson, Susan Eshleman

Research output: Contribution to journalArticle

Abstract

The HIVNET 012 trial in Uganda demonstrated that a regimen of single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. Previous studies show that HIV-1 with one or more NVP resistance (NVPR) mutations can be selected in many women as early as 7 days after single-dose NVP. We evaluated the genetic linkage of NVPR mutations in plasma from women in HIVNET 012 collected 7 days after single-dose NVP administration. The HIV-1 pol region was amplified and cloned from 20 plasma samples (16 with NVPR mutations detected by population sequencing and 4 with no NVPR mutations detected), and 10 clones from each sample were sequenced. Up to five different NVPR mutations were detected in clones from a single sample. K103N and Y181C were the most common mutations detected. Clones with two genetically linked mutations were detected in four samples. Different combinations of NVPR mutations were linked in individual clones, but none of the clones contained both K103N and Y181C. Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume21
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Nevirapine
Genetic Linkage
HIV-1
Mutation
Clone Cells
Uganda
Mothers

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine. / Jones, Dana; Parkin, Neil; Hudelson, Sarah E.; Guay, Laura A.; Musoke, Philippa; Mmiro, Francis; Jackson, J. Brooks; Eshleman, Susan.

In: AIDS Research and Human Retroviruses, Vol. 21, No. 4, 04.2005, p. 319-324.

Research output: Contribution to journalArticle

Jones, Dana ; Parkin, Neil ; Hudelson, Sarah E. ; Guay, Laura A. ; Musoke, Philippa ; Mmiro, Francis ; Jackson, J. Brooks ; Eshleman, Susan. / Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine. In: AIDS Research and Human Retroviruses. 2005 ; Vol. 21, No. 4. pp. 319-324.
@article{deb0e112be0443de8ab5d824926fa399,
title = "Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine",
abstract = "The HIVNET 012 trial in Uganda demonstrated that a regimen of single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. Previous studies show that HIV-1 with one or more NVP resistance (NVPR) mutations can be selected in many women as early as 7 days after single-dose NVP. We evaluated the genetic linkage of NVPR mutations in plasma from women in HIVNET 012 collected 7 days after single-dose NVP administration. The HIV-1 pol region was amplified and cloned from 20 plasma samples (16 with NVPR mutations detected by population sequencing and 4 with no NVPR mutations detected), and 10 clones from each sample were sequenced. Up to five different NVPR mutations were detected in clones from a single sample. K103N and Y181C were the most common mutations detected. Clones with two genetically linked mutations were detected in four samples. Different combinations of NVPR mutations were linked in individual clones, but none of the clones contained both K103N and Y181C. Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant.",
author = "Dana Jones and Neil Parkin and Hudelson, {Sarah E.} and Guay, {Laura A.} and Philippa Musoke and Francis Mmiro and Jackson, {J. Brooks} and Susan Eshleman",
year = "2005",
month = "4",
doi = "10.1089/aid.2005.21.319",
language = "English (US)",
volume = "21",
pages = "319--324",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine

AU - Jones, Dana

AU - Parkin, Neil

AU - Hudelson, Sarah E.

AU - Guay, Laura A.

AU - Musoke, Philippa

AU - Mmiro, Francis

AU - Jackson, J. Brooks

AU - Eshleman, Susan

PY - 2005/4

Y1 - 2005/4

N2 - The HIVNET 012 trial in Uganda demonstrated that a regimen of single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. Previous studies show that HIV-1 with one or more NVP resistance (NVPR) mutations can be selected in many women as early as 7 days after single-dose NVP. We evaluated the genetic linkage of NVPR mutations in plasma from women in HIVNET 012 collected 7 days after single-dose NVP administration. The HIV-1 pol region was amplified and cloned from 20 plasma samples (16 with NVPR mutations detected by population sequencing and 4 with no NVPR mutations detected), and 10 clones from each sample were sequenced. Up to five different NVPR mutations were detected in clones from a single sample. K103N and Y181C were the most common mutations detected. Clones with two genetically linked mutations were detected in four samples. Different combinations of NVPR mutations were linked in individual clones, but none of the clones contained both K103N and Y181C. Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant.

AB - The HIVNET 012 trial in Uganda demonstrated that a regimen of single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. Previous studies show that HIV-1 with one or more NVP resistance (NVPR) mutations can be selected in many women as early as 7 days after single-dose NVP. We evaluated the genetic linkage of NVPR mutations in plasma from women in HIVNET 012 collected 7 days after single-dose NVP administration. The HIV-1 pol region was amplified and cloned from 20 plasma samples (16 with NVPR mutations detected by population sequencing and 4 with no NVPR mutations detected), and 10 clones from each sample were sequenced. Up to five different NVPR mutations were detected in clones from a single sample. K103N and Y181C were the most common mutations detected. Clones with two genetically linked mutations were detected in four samples. Different combinations of NVPR mutations were linked in individual clones, but none of the clones contained both K103N and Y181C. Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant.

UR - http://www.scopus.com/inward/record.url?scp=18244370257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244370257&partnerID=8YFLogxK

U2 - 10.1089/aid.2005.21.319

DO - 10.1089/aid.2005.21.319

M3 - Article

C2 - 15943576

AN - SCOPUS:18244370257

VL - 21

SP - 319

EP - 324

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -